Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;115(3):354-8.
doi: 10.1016/j.oooo.2012.10.012. Epub 2013 Jan 9.

Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients

Affiliations

Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients

Steven D Westbrook et al. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Mar.

Abstract

Objective: We monitored the epidemiology and microbiology of oral yeast colonization in patients undergoing hemopoietic progenitor cell transplantation (HPCT) to examine associations between yeast colonization and oral mucositis.

Study design: One hundred twenty-one consecutive HPCT patients were sampled for oral yeasts prior to fluconazole (FLC) prophylaxis, at transplantation, and weekly until discharge. Clinical oral mucositis screenings were performed triweekly.

Results: Yeast colonization was evident at 216 of 510 total visits. Candida albicans and Candida glabrata were the predominant organisms. Eight patients showed elevated minimal inhibitory concentrations to FLC. One patient developed fungal septicemia. Patients with oral mucositis assessment scale scores <20 had higher colonization rates than those with higher scores.

Conclusions: FLC is effective in controlling a variety of oral yeasts in HPCT recipients. FLC-resistant yeasts do emerge and can be the source of fungal sepsis. A positive association was not shown between yeast colonization and the presence or severity of oral mucositis.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

TFP: Research Support/Consultant: Astellas Pharma US, Merck & Co., Viamet Pharmaceuticals, Inc., Toyama Chemical Company, and Pfizer Inc. SWR: Research Support: Pfizer Inc., Merck & Co., Astellas Pharma US Inc. NPW: Research Support/Consultant: Astellas Pharma US, Merck & Co., CyDex, Viamet Pharmaceuticals, Inc., Toyama Chemical Company, and Pfizer Inc. SDW, WRK, JJT, COF: None to declare.

Figures

Figure 1
Figure 1
Bar graphs represent the incidence of predominant Candida species found in the total patient population for each visit. Percentages do not equal 100% due to mixed cultures. Line graph represents the percentage of patients who were neutropenic (< 1000 cells/mL) at each visit.

References

    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26. - PubMed
    1. Epstein JB, Raber-Durlacher JE, Wilkins A, Chavarria MG, Myint H. Advances in hematologic stem cell transplant: an update for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:301–12. - PubMed
    1. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100. - PubMed
    1. Marr KA, Bow E, Chiller T, Maschmeyer G, Ribaud P, Segal B, et al. Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44:483–7. - PubMed
    1. Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia. 2009;168:299–311. - PubMed

Publication types

MeSH terms